On the public citation graph

The effects of monoclonal anti‐CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia

https://doi.org/10.1111/trf.15397
0 signed · 126 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.cell.2009.05.045openalex-snapshot
CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells
inferredcites →https://doi.org/10.1016/j.it.2010.04.001openalex-snapshot
Macrophages as mediators of tumor immunosurveillance
inferredcites →https://doi.org/10.1016/j.it.2017.12.005openalex-snapshot
SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy
inferredcites →https://doi.org/10.1038/nm.3965openalex-snapshot
CD47 blockade as another immune checkpoint therapy for cancer
inferredcites →https://doi.org/10.1056/nejmc1515969openalex-snapshot
Interference of New Drugs with Compatibility Testing for Blood Transfusion
inferredcites →https://doi.org/10.1056/nejmc1804751openalex-snapshot
F(ab′) 2 Fragments to Overcome Daratumumab Interference in Transfusion Tests
inferredcites →https://doi.org/10.1056/nejmoa1807315openalex-snapshot
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
inferredcites →https://doi.org/10.1073/pnas.1121623109openalex-snapshot
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
inferredcites →https://doi.org/10.1080/1042819042000201989openalex-snapshot
Role of CD47 in Erythroid Cells and in Autoimmunity
inferredcites →https://doi.org/10.1111/j.1365-2141.1977.tb08818.xopenalex-snapshot
IgG4 Autoantibodies against Erythrocytes, without Increased Haemolysis: a Case Report
inferredcites →https://doi.org/10.1111/trf.13069openalex-snapshot
Resolving the daratumumab interference with blood compatibility testing
inferredcites →https://doi.org/10.1111/trf.15033openalex-snapshot
Monoclonal anti‐CD47 interference in red cell and platelet testing
inferredcites →https://doi.org/10.1126/science.288.5473.2051openalex-snapshot
Role of CD47 as a Marker of Self on Red Blood Cells
inferredcites →https://doi.org/10.1182/blood-2018-99-115674openalex-snapshot
RBC-Specific CD47 Pruning Confers Protection and Underlies the Transient Anemia in Patients Treated with Anti-CD47 Antibody 5F9
inferredcites →https://doi.org/10.1182/blood-2018-99-120170openalex-snapshot
Combination Treatment with 5F9 and Azacitidine Enhances Phagocytic Elimination of Acute Myeloid Leukemia
inferredcites →https://doi.org/10.1182/blood.v99.10.3500openalex-snapshot
Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice
inferredcites →https://doi.org/10.1200/jco.2018.36.15_suppl.3002openalex-snapshot
A first-in-class, first-in-human phase 1 pharmacokinetic (PK) and pharmacodynamic (PD) study of Hu5F9-G4, an anti-CD47 monoclonal antibody (mAb), in patients with advanced solid tumors.
inferredcites →https://doi.org/10.1200/jco.2019.37.15_suppl.7009openalex-snapshot
The first-in-class anti-CD47 antibody Hu5F9-G4 is active and well tolerated alone or with azacitidine in AML and MDS patients: Initial phase 1b results.
inferredcites →https://doi.org/10.1371/journal.pone.0137345openalex-snapshot
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4628680openalex-extracted
Disruption of CD47-SIRPα Signalling Restores Inflammatory Function in Tumour-Associated Myeloid Derived Suppressor Cells
inferred← citeshttps://doi.org/10.1002/adfm.202411439openalex-snapshot
Leukemia Cell Hitchhiking Hypoxia Responsive Nanogel for Improved Immunotherapy of Acute Myeloid Leukemia
inferred← citeshttps://doi.org/10.1002/adfm.202503583openalex-snapshot
Differentiation Responsive Architected Macrophage (DREAM) Selectively Modulate Tumor Microenvironment for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/ange.202318544openalex-snapshot
Activation of RIG‐I/MDA5 Signaling and Inhibition of CD47‐SIRPα Checkpoint with a Dual siRNA‐Assembled Nanoadjuvant for Robust Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/anie.202318544openalex-snapshot
Activation of RIG‐I/MDA5 Signaling and Inhibition of CD47‐SIRPα Checkpoint with a Dual siRNA‐Assembled Nanoadjuvant for Robust Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1002/mco2.192openalex-snapshot
Targeting inorganic nanoparticles to tumors using biological membrane‐coated technology
inferred← citeshttps://doi.org/10.1007/978-3-030-54058-6_7openalex-snapshot
Transfusion in Pregnant Patients Receiving Treatment for Leukemia
inferred← citeshttps://doi.org/10.1007/978-3-031-75810-2_20openalex-snapshot
Transfusion Medicine Consultation
inferred← citeshttps://doi.org/10.1007/s00262-023-03465-9openalex-snapshot
The TSP1-CD47-SIRPα interactome: an immune triangle for the checkpoint era
inferred← citeshttps://doi.org/10.1007/s00277-021-04734-2openalex-snapshot
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes
inferred← citeshttps://doi.org/10.1007/s10555-020-09943-1openalex-snapshot
Macrophages in multiple myeloma: key roles and therapeutic strategies
inferred← citeshttps://doi.org/10.1007/s12672-025-01797-9openalex-snapshot
Revolutionizing acute myeloid leukemia treatment: a systematic review of immune-based therapies
inferred← citeshttps://doi.org/10.1007/s44178-024-00122-8openalex-snapshot
Guideline for ethics review of clinical trials
inferred← citeshttps://doi.org/10.1016/bs.acr.2025.06.005openalex-snapshot
In search of a targetable immune profile for acute myeloid leukemia
inferred← citeshttps://doi.org/10.1016/j.bbcan.2020.188434openalex-snapshot
Targeting tumor-associated macrophages for cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.bbrc.2026.153330openalex-snapshot
Clinical advances in CD47-SIRPα axis-targeted cancer immunotherapy: Mechanisms, strategies, challenges, and future perspectives
inferred← citeshttps://doi.org/10.1016/j.biopha.2023.114618openalex-snapshot
High-affinity decoy protein, nFD164, with an inactive Fc region as a potential therapeutic drug targeting CD47
inferred← citeshttps://doi.org/10.1016/j.biopha.2024.116132openalex-snapshot
Immunotherapies of acute myeloid leukemia: Rationale, clinical evidence and perspective
inferred← citeshttps://doi.org/10.1016/j.blre.2020.100709openalex-snapshot
Immune checkpoint inhibition in myeloid malignancies: Moving beyond the PD-1/PD-L1 and CTLA-4 pathways
inferred← citeshttps://doi.org/10.1016/j.blre.2023.101055openalex-snapshot
TP53 in AML and MDS: The new (old) kid on the block
inferred← citeshttps://doi.org/10.1016/j.blre.2026.101391openalex-snapshot
Immunotherapy in acute myeloid leukemia: The antibodies, TriKEs, and CARs on the arduous road to cure
inferred← citeshttps://doi.org/10.1016/j.ccell.2023.10.007openalex-snapshot
The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2020.102993openalex-snapshot
Targeting acute myeloid leukemia stem cells: Current therapies in development and potential strategies with new dimensions
inferred← citeshttps://doi.org/10.1016/j.csbj.2021.09.036openalex-snapshot
Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy
inferred← citeshttps://doi.org/10.1016/j.drup.2023.101041openalex-snapshot
The promising role of tumor-associated macrophages in the treatment of cancer
inferred← citeshttps://doi.org/10.1016/j.heliyon.2023.e22905openalex-snapshot
The role of CD47 in non-neoplastic diseases
inferred← citeshttps://doi.org/10.1016/j.intimp.2023.110255openalex-snapshot
The CD47-SIRPα axis is a promising target for cancer immunotherapies
inferred← citeshttps://doi.org/10.1016/j.iotech.2022.100070openalex-snapshot
CD47–SIRPα-targeted therapeutics: status and prospects
inferred← citeshttps://doi.org/10.1016/j.isci.2024.109546openalex-snapshot
Disruption of CD47-SIRPα signaling restores inflammatory function in tumor-associated myeloid-derived suppressor cells
inferred← citeshttps://doi.org/10.1016/j.jare.2023.10.009openalex-snapshot
Deciphering the role of CD47 in cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.jconrel.2022.09.042openalex-snapshot
Advantage of extracellular vesicles in hindering the CD47 signal for cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.lfs.2021.119150openalex-snapshot
The role of CD47-SIRPα immune checkpoint in tumor immune evasion and innate immunotherapy
inferred← citeshttps://doi.org/10.1016/j.lrr.2021.100268openalex-snapshot
CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies
inferred← citeshttps://doi.org/10.1016/j.pathol.2021.01.001openalex-snapshot
Impact of new myeloma agents on the transfusion laboratory
inferred← citeshttps://doi.org/10.1016/j.pathol.2025.04.008openalex-snapshot
Novel strategy for overcoming interference from anti-CD47 agents in pretransfusion testing
inferred← citeshttps://doi.org/10.1016/j.tracli.2024.10.004openalex-snapshot
Recommandations pour la réalisation des examens d’immuno-hématologie de première intention par les laboratoires médicaux
inferred← citeshttps://doi.org/10.1038/s41392-024-01826-zopenalex-snapshot
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
inferred← citeshttps://doi.org/10.1038/s41392-025-02124-yopenalex-snapshot
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets
inferred← citeshttps://doi.org/10.1038/s41568-025-00893-wopenalex-snapshot
Targeting phagocytosis checkpoints for cancer immunotherapy
inferred← citeshttps://doi.org/10.1080/14728214.2022.2094365openalex-snapshot
Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials
inferred← citeshttps://doi.org/10.1080/14728222.2020.1811855openalex-snapshot
Blockade of CD47 or SIRPα: a new cancer immunotherapy
inferred← citeshttps://doi.org/10.1080/21645515.2021.1898307openalex-snapshot
Myelodysplastic syndrome and immunotherapy novel to next in-line treatments
inferred← citeshttps://doi.org/10.1097/hs9.0000000000000914openalex-snapshot
An Overview of Targeted Therapies in Acute Myeloid Leukemia
inferred← citeshttps://doi.org/10.1097/moh.0000000000000749openalex-snapshot
Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia
inferred← citeshttps://doi.org/10.1111/bjh.19664openalex-snapshot
Blood group genotype matching for transfusion
inferred← citeshttps://doi.org/10.1111/ijlh.14252openalex-snapshot
Transient red blood cell agglutination after Magrolimab administration in acute myeloid leukemia
inferred← citeshttps://doi.org/10.1111/imj.15934openalex-snapshot
Guidance for transfusion management in patients receiving magrolimab therapy (anti‐CD47 monoclonal antibody)
inferred← citeshttps://doi.org/10.1111/tme.12664openalex-snapshot
Two case reports involving therapeutic monoclonal anti‐CD47 (Hu5F9‐G4), it's effect on compatibility testing and subsequent selection of components for transfusion
inferred← citeshttps://doi.org/10.1111/trf.15848openalex-snapshot
Current advances in transfusion medicine: a 2019 review of selected topics from the AABB Clinical Transfusion Medicine Committee
inferred← citeshttps://doi.org/10.1111/trf.16009openalex-snapshot
Assessing and mitigating the interference of ALX148 , a novel CD47 blocking agent, in pretransfusion compatibility testing
inferred← citeshttps://doi.org/10.1111/trf.16425openalex-snapshot
Optimizing transfusion management of multiple myeloma patients receiving daratumumab‐based regimens
inferred← citeshttps://doi.org/10.1111/trf.16825openalex-snapshot
Alloimmunization rates in transfused patients receiving anti‐CD47 antibody therapy
inferred← citeshttps://doi.org/10.1111/trf.17137openalex-snapshot
Anti‐CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping
inferred← citeshttps://doi.org/10.1111/trf.17307openalex-snapshot
The need for rare blood programs is real
inferred← citeshttps://doi.org/10.1111/trf.17597openalex-snapshot
Transfusion management in the era of magrolimab ( Hu5F9‐G4 ), an anti‐ CD47 monoclonal antibody therapy
inferred← citeshttps://doi.org/10.1111/trf.17880openalex-snapshot
How do transfusion services manage patients taking therapies such as anti‐ CD38 and anti‐ CD47 known to interfere with red blood cell compatibility testing?
inferred← citeshttps://doi.org/10.1111/trf.18367openalex-snapshot
Anti‐ CD47 drug interference in pre‐transfusion testing can be overcome by antigen masking
inferred← citeshttps://doi.org/10.1111/trf.70382openalex-snapshot
Pretransfusion testing interference profile of IMC ‐002: A novel anti‐ CD47 monoclonal antibody engineered for minimized red cell binding
inferred← citeshttps://doi.org/10.1126/sciadv.ade3942openalex-snapshot
CD47 halts Ptpn6 -deficient neutrophils from provoking lethal inflammation
inferred← citeshttps://doi.org/10.1126/scitranslmed.abn1128openalex-snapshot
Intracavity generation of glioma stem cell–specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy
inferred← citeshttps://doi.org/10.1158/1078-0432.ccr-25-0434openalex-snapshot
Facts and Hopes in Harnessing Macrophage-Mediated Antibody-Dependent Cellular Phagocytosis for Cancer Immunotherapy
inferred← citeshttps://doi.org/10.1158/2326-6066.cir-19-0493openalex-snapshot
CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive Immunity
inferred← citeshttps://doi.org/10.1159/000517565openalex-snapshot
Application of Blood Group Genotyping by Next-Generation Sequencing in Various Immunohaematology Cases
inferred← citeshttps://doi.org/10.1159/000534273openalex-snapshot
Evorpacept-Induced Interference and Application of a Novel Mitigation Agent, Evo-NR, in Pretransfusion Testing
inferred← citeshttps://doi.org/10.1177/10732748231159706openalex-snapshot
Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian Cancer
inferred← citeshttps://doi.org/10.1177/2040620720955006openalex-snapshot
Emerging treatment options for patients with high-risk myelodysplastic syndrome
inferred← citeshttps://doi.org/10.1186/s12943-023-01714-0openalex-snapshot
Regulatory cells and the effect of cancer immunotherapy
inferred← citeshttps://doi.org/10.1186/s12964-023-01384-xopenalex-snapshot
Targeting the macrophage immunocheckpoint: a novel insight into solid tumor immunotherapy
inferred← citeshttps://doi.org/10.1186/s13045-020-00930-1openalex-snapshot
Role of CD47 in Hematological Malignancies
inferred← citeshttps://doi.org/10.1186/s40364-023-00456-xopenalex-snapshot
The landscape overview of CD47-based immunotherapy for hematological malignancies
inferred← citeshttps://doi.org/10.1200/jco.22.02604openalex-snapshot
Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
inferred← citeshttps://doi.org/10.12182/20210960501openalex-snapshot
[Tracking Research Progress in the Modulatory Role of Gut Microbiome in Immune Checkpoint Inhibitors Applied in Cancer Treatment].
inferred← citeshttps://doi.org/10.17945/kjbt.2023.34.1.26openalex-snapshot
Elimination of ALX148 Interference in Pretransfusion Testing by RBC Alloadsorption: Two Case Reports
inferred← citeshttps://doi.org/10.20517/cdr.2021.140openalex-snapshot
Characteristics of leukemic stem cells in acute leukemia and potential targeted therapies for their specific eradication
inferred← citeshttps://doi.org/10.2450/bloodtransfus.539openalex-snapshot
Pretreatment with Daudi cells eliminates anti-CD47 monoclonal antibody interference in immunohematology testing.
inferred← citeshttps://doi.org/10.3389/fgene.2022.988703openalex-snapshot
The soldiers needed to be awakened: Tumor-infiltrating immune cells
inferred← citeshttps://doi.org/10.3389/fimmu.2021.614294openalex-snapshot
The Iron Curtain: Macrophages at the Interface of Systemic and Microenvironmental Iron Metabolism and Immune Response in Cancer
inferred← citeshttps://doi.org/10.3389/fimmu.2022.1027235openalex-snapshot
Inhibition of the CD47-SIRPα axis for cancer therapy: A systematic review and meta-analysis of emerging clinical data
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1803185openalex-snapshot
From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia
inferred← citeshttps://doi.org/10.3389/fonc.2026.1838900openalex-snapshot
UBA1 enhances phagocytosis by suppressing CD47 expression in small cell lung cancer
inferred← citeshttps://doi.org/10.3390/antib9030044openalex-snapshot
CD47 as a Potential Target to Therapy for Infectious Diseases
inferred← citeshttps://doi.org/10.3390/cancers12123742openalex-snapshot
Acute Myeloid Leukemia Stem Cells: The Challenges of Phenotypic Heterogeneity
inferred← citeshttps://doi.org/10.3390/cancers13195026openalex-snapshot
Immune Therapies for Myelodysplastic Syndromes and Acute Myeloid Leukemia
inferred← citeshttps://doi.org/10.3390/cancers13246229openalex-snapshot
Cancer Therapy Targeting CD47/SIRPα
inferred← citeshttps://doi.org/10.3390/cancers14143366openalex-snapshot
Targeting the CD47-SIRPα Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils
inferred← citeshttps://doi.org/10.3390/cancers14235906openalex-snapshot
Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia
inferred← citeshttps://doi.org/10.3390/cancers15102717openalex-snapshot
Anti-Tumor Strategies by Harnessing the Phagocytosis of Macrophages
inferred← citeshttps://doi.org/10.3390/cancers15112958openalex-snapshot
Novel Investigational Agents and Pathways That May Influence the Future Management of Acute Myeloid Leukemia
inferred← citeshttps://doi.org/10.3390/cancers15205060openalex-snapshot
Immunotherapy with Monoclonal Antibodies for Acute Myeloid Leukemia: A Work in Progress
inferred← citeshttps://doi.org/10.3390/cancers18111808openalex-snapshot
Myeloid Malignancies Beyond the Cell: Targeting the Tumour Microenvironment with Next-Generation Immunotherapies
inferred← citeshttps://doi.org/10.3390/cells11010139openalex-snapshot
Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias
inferred← citeshttps://doi.org/10.3390/cells11223591openalex-snapshot
Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
inferred← citeshttps://doi.org/10.3390/cells8121526openalex-snapshot
Tumor-Associated Macrophages in Hematologic Malignancies: New Insights and Targeted Therapies
inferred← citeshttps://doi.org/10.3390/hemato5030018openalex-snapshot
Interference of Monoclonal Antibody Therapy in Transfusion: An Update
inferred← citeshttps://doi.org/10.3390/ijms22041944openalex-snapshot
Emerging Immunotherapy for Acute Myeloid Leukemia
inferred← citeshttps://doi.org/10.3390/ijms23147542openalex-snapshot
New Frontiers in Monoclonal Antibodies for the Targeted Therapy of Acute Myeloid Leukemia and Myelodysplastic Syndromes
inferred← citeshttps://doi.org/10.3390/pathogens10020134openalex-snapshot
Role of Apoptotic Cell Clearance in Pneumonia and Inflammatory Lung Disease
inferred← citeshttps://doi.org/10.34091/ajls.3.2.11openalex-snapshot
Treatment of Acute Myeloid Leukemia: A Concise Overview
inferred← citeshttps://doi.org/10.3410/f.739354841.793585660openalex-snapshot
Faculty Opinions recommendation of Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells.
inferred← citeshttps://doi.org/10.36468/pharmaceutical-sciences.spl.606openalex-snapshot
The Interference of Monoclonal Anti-Cluster of Differentiation 47 on Transfusion Compatibility Testing
inferred← citeshttps://doi.org/10.3892/ol.2024.14389openalex-snapshot
Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review)
inferred← citeshttps://doi.org/10.3925/jjtc.67.440openalex-snapshot
A MULTI-INSTITUTIONAL COLLABORATIVE STUDY OF PRETRANSFUSION TESTS IN PATIENTS WHO RECEIVED ANTI-CD38 THERAPY
inferred← citeshttps://doi.org/10.4049/jimmunol.2001019openalex-snapshot
Novel SIRPα Antibodies That Induce Single-Agent Phagocytosis of Tumor Cells while Preserving T Cells
inferred← citeshttps://doi.org/10.47429/lmo.2020.10.4.330openalex-snapshot
Elimination of Anti-CD47 Interference in Pretransfusion Testing by Multiple Platelet Alloadsorption: A Case Report
inferred← citeshttps://doi.org/10.5772/intechopen.1003886openalex-snapshot
Breaking Barriers: Unleashing the Potential of ABO Blood Group Antigen Therapy in the Battle against Solid Tumors
inferred← citeshttps://doi.org/10.70675/2837df51zc15bz4221zb82fzc9f2a9e1008aopenalex-snapshot
Ciblage thérapeutique de ALK et de CD47 dans le lymphome anaplasique à grandes cellules ALK-positif
inferred← citeshttps://doi.org/10.70675/3fa46295z82c6z4bbcz8ec0zfd9c30b63f3fopenalex-snapshot
Potentiel thérapeutique d’un peptide antagoniste de l’interaction TSP-1 : CD47 dans la thrombose artérielle et sur les effets potentialisateurs des plaquettes dans la progression tumorale
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.